Trastuzumab deruxtecan

T-DXd improved progression-free survival (PFS) vs treatment of physician's choice (TPC) in patients with hormone receptor–positive, HER2-low/-ultralow metastatic breast cancer, regardless of time to progression (TTP) on frontline endocrine therapy plus CDK4/6 inhibition and type of endocrine resistance, according to the phase 3 DESTINY-Breast06 trial. Median PFS ranged from 12.4 to 14.0 months with T-DXd vs 6.5 to 9.5 months with TPC across different TTP and endocrine resistance subgroups. T-DXd also improved objective response rate (ORR) and duration of response (DOR) vs TPC, with median PFS2 of 20.3 months vs 14.7 months. T-DXd demonstrated efficacy regardless of disease burden and safety profiles consistent with the overall population.

AstraZeneca and Daiichi Sankyo's Dato-DXd received FDA Breakthrough Therapy designation for EGFRm NSCLC, based on phase II and III study data. They submitted a new BLA for accelerated approval in this indication and withdrew an earlier BLA for nonsquamous NSCLC. Dato-DXd is also under review for HR+ HER2- breast cancer, with regulatory applications ongoing globally.

GLP-1 drugs like semaglutide and tirzepatide have expanded uses beyond diabetes and weight loss, potentially treating cardiovascular disease, kidney disease, anxiety, depression, and substance use disorder. CRISPR drugs Casgevy for sickle cell disease and β-thalassemia entered the market, though uptake is slow due to complex treatment processes. Protein-folding algorithms by Baker, Hassabis, and Jumper revolutionized biochemical research and pharmaceutical applications. ADCs received significant investment, with firms exploring new linker chemistries. Amylyx Pharmaceuticals pulled an ALS drug after trial failure, continuing research for other uses. Kelly Chibale called for recognizing African scientific potential. Virologists monitored H5N1, mpox, and Marburg outbreaks, with ongoing research and emergency measures. Radiopharmaceuticals saw increased investment and market growth. Evidence suggests vaccines like shingles and flu jabs may protect against dementia.

Cathy Eng, MD, FACP, FASCO, discussed biomarker testing, sequencing strategies, and clinical trial data for colorectal cancer (CRC) at the 42nd Annual Chemotherapy Foundation Symposium. Eng emphasized the importance of next-generation sequencing (NGS) and circulating tumor DNA (ctDNA) in informing treatment decisions. She highlighted data from the CheckMate-8HW and MOUNTAINEER-03 trials, and the role of immunotherapy and antibody-drug conjugates in CRC treatment. Eng also discussed the evolving use of ctDNA testing and the critical importance of NGS for all CRC patients.

AstraZeneca's Imfinzi approved in the US for limited-stage small cell lung cancer (LS-SCLC) after chemotherapy and radiation, based on ADRIATIC trial results showing improved survival and reduced risk of death and disease progression.

Hyunji Kim, a breast cancer patient, is in a clinical trial for LCB84, an antibody-drug conjugate, which has stabilized her liver metastasis. Dr. Yuan Yuan describes antibody-drug conjugates as designer drugs targeting specific cancer cells. Over 150 such conjugates are in trials, with Kadcyla, Enhertu, and Trodelvy approved for breast cancer. The field offers hope for chemotherapy-resistant diseases, with ongoing research exploring various targets and payloads.

Enhertu, a breakthrough breast cancer drug, is expected to significantly improve the lives of HER2-positive advanced cancer patients by extending life and stability of cancer. Additionally, osimertinib for lung cancer and palivizumab for RSV in babies are set to benefit numerous patients, while a new inhaler for COPD will improve the quality of life for many New Zealanders.

Imfinzi (durvalumab) is a PD-L1 inhibitor used in various cancer treatments, including NSCLC, SCLC, biliary tract cancer, and endometrial cancer. AstraZeneca, a global biopharmaceutical company, focuses on oncology, rare diseases, and bio-pharmaceuticals, aiming to redefine cancer care and eliminate it as a cause of death.

DelveInsight's HER2+ Gastric Cancer Market Insights, Epidemiology, and Market Forecast-2032 report details historical and forecasted epidemiology, market trends in the US, EU5, and Japan. Key companies include Roche, Elevar Therapeutic, Bristol-Myers Squibb, Merck, and Daiichi Sankyo. Therapies like SHR-A1811, Cinrebafusp alfa, and BI-1607 are highlighted. Regulatory approvals for KN026 and Enhertu are noted, with market growth expected due to increasing prevalence and pipeline product launches.

Imfinzi (durvalumab) is a PD-L1 inhibitor used in various cancer treatments, including NSCLC, SCLC, biliary tract cancer, and endometrial cancer. AstraZeneca is a leader in oncology, focusing on early detection and innovative treatments for lung cancer and immuno-oncology, aiming to redefine cancer care and eliminate it as a cause of death.